-参考文献-
[1]Vilsboll T∙ On the role of the incretin hormones GIP and GLP-1in the pathogenesis of type 2 diabetes mellitusc∙ Dan Med Bull [J]. 2004,51(4):364-370.

[2] Drucker DJ∙ Minireview：the glucagon-like peptides［J］∙Endocrinolo-gy,2001,142(2):521-527.

[3] Wasada T∙[Glucagon-like peptide-1（GLP-1）][J]∙Nippon Rinsho,2004,62(6):1175-1180.

[4] 金玉翠,申传安,柴家科.胰高血糖素样肽1的结构及生物学作用研究进展[J].解放军医学杂志,2011,36(08):875-878.

[5] Pannacciulli N, Le DS, Salbe AD, et a∙l Postprandial glucagon-like peptide-1(GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans［J］Neuroimage,2007,35（2）：511-517

[6] Meier JJ, Kemmeries G, Holst JJ, et a∙l Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide1and un masks its insulinotropic effect in healthy subjects［J］∙Diabetes, 2005, 54（7）：2212-2218

[7] Acitores A, Gonzalez N, Sancho V, et a∙l Cell signalling of glucagon like peptide-1action in rat skeletal muscle［J］∙ J Endocrinol, 2004, 180（3）：389-398

[8] Luque MA, Gonzalez N, Marquez L, et a∙l Glucagon-like peptide-1（GLP-1）and glucose metabolism in human myocytes［J］∙ J Endocrinol, 2002, 173（3）：465-473∙

[9] Arnes L, Gonzalez N, Tornero-Esteban P, et a∙l Characteristics of GLP-1and exendins action upon glucose transport and metabolism in type2diabetic rat skeletal muscle［J］∙Int J Mol Med, 2008, 22（1）: 127-132

[10] PEARSONS, KIETSIRIROJE N, AJJAN RA．Oral semaglutide in the management of type 2 diabetes: a report on the evidence to date［J］．Diabetes Metab Syndr Obes，2019，12: 2515 － 2529．

[11] HUSAIN M, BIRKENFELD AL，DONSMARK M, et al．Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes［J］．N Engl J Med，2019，381: 841－851．

[12]JUNG KK，YOUNG JP，KWON SC，et al． Once-weekly Combi-nation of GLP-1R Agonist and Insulin ( HM14220 ) Offers Imwproved Glycemic Control and Reduced Weight Gain Risk［C］//75th Scientific Sessions of the American-Diabetes-Association, Volume: 64 Boston，Massachusetts, 2015．

[13] TAN TM，SALEM V，TROKE RC，et al．Combination of pepttide YY3-36 with GLP-1( 7-36) amide causes an increase in first-phase insulin secretion after IV glucose［J］. J Clin Endocrinol Metab, 2014, 99( 11) : E2317－E2324．

[14] FRIAS JP, BASTYR EJ III, VIGNATI L, et al. The sustained effects of a dual GIP /GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes［J］．Cell Metab, 2017, 26( 2) : 343－352．

[15] Gupta NA, Mells J, Dunham RM, et a∙l Glucagon-like peptide-1receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway ［J］∙ Hepatology, 2010, 51（5）: 1584-1592.

[16] Yu Z,Jin T∙ New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1（GLP-1）[J]. Cell Signal, 2010,22(1);1-8.

[17]胰腺高血糖素样肽-1受体激动剂（GLP-1RA）临床应用医药专家共识（广东省药学会2023年4月21日发布）.

[18]潘琦, 郭立新. 胰高糖素样肽-1受体激动剂的发展历程和临床应用进展 [J] . 中华糖尿病杂志, 2022, 14(12) : 1355-1363. DOI: 10.3760/cma.j.cn115791-20220802-00375.

[19] IDF Diabetes Atlas 10th edition.

[20] 西南证券：GLP-1引领全球降糖药时代变革.